|
Synonyms: MGA-271 | MGA271
Compound class:
Antibody
Comment: Enoblituzumab (MGA271) is a humanized IgG1κ mAb with enhanced ADCC. Its target is the B7-H3 (CD276) member of the B7 family of immune regulators [2]. It has been engineered to enhance effector-mediated antitumor function via increased affinity for the activating receptor CD16A (FcγRIII) and decreased binding to the inhibitory receptor CD32B (FcγRIIB).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST sequence analysis identifies exact matches with antibody peptides claimed in patent US8802091, and specifically with a construct designated as hBRCA84D-2 [1]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 10165 | enoblituzumab |
| Synonyms |
| MGA-271 | MGA271 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 590 |
| Other databases | |
| GtoPdb PubChem SID | 340590220 |
| Search PubMed clinical trials | enoblituzumab |
| Search PubMed titles | enoblituzumab |
| Search PubMed titles/abstracts | enoblituzumab |
